SGMO

Sangamo Therapeutics, Inc., a clinical-stage genomic medicine company, focuses on translating science into medicines that transform the lives of patients and families afflicted with serious diseases in the United States. The company's clinical-stage product candidates are ST-920, a gene therapy product candidate, which is in Phase 1/2 clinical study for the treatment of Fabry disease; small fiber neuropathy for chronic neuropathic pain, and prion disease; Phase 1/2 clinical trial to evaluate the safety and tolerability of the investigational genetically modified cell therapy TX200 in patients undergoing a kidney transplant.; SB-525, a gene therapy product candidate, which is in Phase 3 clinical trial for the treatment of moderately severe to severe hemophilia A; giroctocogene fitelparvovec, a Phase 3 study to evaluate the clinical efficacy and safety of giroctocogene fitelparvovec gene therapy in adult male with moderately severe or severe hemophilia A. Sangamo Therapeutics, Inc. has collaborative and strategic partnerships with Genentech, Inc.; Astellas Gene Therapies, Inc.; Capsid Delivery License Agreement with Eli Lilly and Company; Alexion Pharmaceuticals, Inc. – ALS and Frontotemporal Lobar Degeneration; Takeda – Huntington's Disease; and other areas, such as plant agriculture and research reagents, including the production of transgenic animals and cell-line engineering with Corteva AgriScience and Open Monoclonal Technology, Inc. The company was formerly known as Sangamo BioSciences, Inc. and changed its name to Sangamo Therapeutics, Inc. in January 2017. The company was incorporated in 1995 and is headquartered in Richmond, California.